|Bid||28.35 x 0|
|Ask||29.04 x 0|
|Day's range||28.29 - 28.35|
|52-week range||15.20 - 31.28|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Here's why AstraZeneca agreed to pay Daiichi Sankyo another enormous sum to develop and commercialize an experimental cancer drug.